STAT3 dominant-negative disease (STAT3DN)—also known as autosomal dominant hyper-IgE syndrome (AD-HIES) or Job’s Syndrome—has widespread deleterious effects on patients’ health. NIAID-supported research seeks to determine the effect of STAT3DN on the immune system, including which immune cells and responses are affected and how these abnormalities translate into patients’ symptoms.
Current Clinical Research Studies Seeking Volunteers
The following are selected clinical trials supported by NIAID and investigating topics related to STAT3DN. The links lead to full study descriptions, eligibility criteria and contact information.
This study is enrolling patients and families with a confirmed or suspected diagnosis of a hyper-immunoglobulin E syndrome (HIES), including STAT3DN, for extensive phenotypic and genotypic study as well as disease management. Findings from this study may help identify further genetic etiologies and gain a better understanding of the pathogenesis of HIES.
This study is enrolling people with STAT3DN, cystic fibrosis, and non-tuberculous mycobacterial (NTM) infections to compare the features of these diseases, which all involve recurrent infections of the lungs and possibly other organs.
Read about NIAID research on STAT3 dominant-negative disease.